US Food and Drug Administration's Division of Biologic Oncology Products has approved two new biologics license application (BLA) supplements expanding the approval of Genentech's Herceptin (trastuzumab) for the treatment of breast cancer.
Formulation and Drug Delivery, Specialty Dosage Forms
Latest News
Advertisement
Advertisement
The transdermal delivery of biologics-as well as of conventional drugs-is growing in popularity because the technique offers numerous advantages.
Advertisement
Advertisement
Trending on BioPharm International
1
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
2
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
3
AAPS 2026 PharmSci 360 Video Recap: AI Transparency, Oral Peptides, and New Models
4
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
5